Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.47 |
| ▸ | PDE4A | P27815 | 5/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | BCL9 | O00512 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021946 | 0.87 | PDE4D (0.54) | PDE5APDE4DPDE4APDE4BPDE4C | |
| SCHEMBL18152308 | 0.84 | BCL9 (0.46) | SLC6A3SLC6A2SLC6A4PLAUBCL9 | |
| SCHEMBL18152310 | 0.84 | BCL9 (0.46) | SLC6A3SLC6A2SLC6A4PLAUBCL9 | |
| SCHEMBL20021952 | 0.83 | PDE4A (0.64) | PDE5APDE4DPDE4APDE4BPDE4C | |
| SCHEMBL30012049 | 0.80 | PIK3CD (0.46) | PDE4DPDE4APDE4BPDE4CBCL9 | |
| SCHEMBL3684452 | 0.80 | CCNC (0.49) | SLC6A3SLC6A2SLC6A4PDE4DPDE4A | |
| SCHEMBL3886842 | 0.79 | CCNC (0.48) | SLC6A3SLC6A2SLC6A4PDE4DPDE4A | |
| SCHEMBL19510615 | 0.77 | FFAR4 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL30350584 | 0.77 | FFAR4 (0.65) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL30462928 | 0.77 | FFAR4 (0.65) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | SLC6A3 4714/4885SLC6A2 4815/4885SLC6A4 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.